98 related articles for article (PubMed ID: 10336293)
1. The Di Bella multitherapy trial. Criticism ignores standard methodology of cancer treatments.
Raschetti R; Greco D; Menniti-Ippolito F; Spila-Alegiani S; Benagiano G; Bruzzi P
BMJ; 1999 Apr; 318(7190):1074. PubMed ID: 10336293
[No Abstract] [Full Text] [Related]
2. Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails.
Italian Study Group for the Di Bella Multitherapy Trials
BMJ; 1999 Jan; 318(7178):224-8. PubMed ID: 9915729
[TBL] [Abstract][Full Text] [Related]
3. The Di Bella multitherapy trial. Randomised controlled trials may not always be absolutely needed.
Liberati A; Magrini N; Patoia L; Pagliaro L
BMJ; 1999 Apr; 318(7190):1073-4; author reply 1074. PubMed ID: 10205115
[No Abstract] [Full Text] [Related]
4. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
5. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
Mazumdar M; Fazzari M; Panageas KS
Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
7. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
8. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.
Kimmick GG; Peterson BL; Kornblith AB; Mandelblatt J; Johnson JL; Wheeler J; Heinze R; Cohen HJ; Muss HB
J Clin Oncol; 2005 Apr; 23(10):2201-7. PubMed ID: 15800312
[TBL] [Abstract][Full Text] [Related]
9. Examining heterogeneity in phase II trial designs may improve success in phase III.
Tuma RS
J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
[No Abstract] [Full Text] [Related]
10. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
Mooney MM; Schoenfeldt M
Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
[No Abstract] [Full Text] [Related]
12. [An index of understanding randomised clinical trials in oncology].
Leroy T; Christophe V; Penel N; Antoine P; Vanlemmens L; Reich M; Clisant S
Bull Cancer; 2009 Jun; 96(6):741-50. PubMed ID: 19467958
[TBL] [Abstract][Full Text] [Related]
13. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/ TRICARE; coverage of phase II and phase III clinical trials sponsored by the National Institutes of Health National Cancer Institute. Final rule.
Office of the Secretary, DoD
Fed Regist; 2006 Jun; 71(118):35389-91. PubMed ID: 16795948
[TBL] [Abstract][Full Text] [Related]
14. A flexible design for multiple armed screening trials.
Sargent DJ; Goldberg RM
Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
[TBL] [Abstract][Full Text] [Related]
15. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
Sakamoto J; Morita S
Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
[TBL] [Abstract][Full Text] [Related]
16. Epothilones and the next generation of phase III trials for prostate cancer.
Bhandari MS; Hussain M
BJU Int; 2005 Aug; 96(3):296-302. PubMed ID: 16042717
[No Abstract] [Full Text] [Related]
17. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
18. The challenges of randomized trials in integrative cancer care.
Block KI; Cohen AJ; Dobs AS; Ornish D; Tripathy D
Integr Cancer Ther; 2004 Jun; 3(2):112-27. PubMed ID: 15165498
[No Abstract] [Full Text] [Related]
19. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
20. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
Tamm I
Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
